Drug intelligence / Profile preview

F230

Development stage: Phase 1
Lead developer: Gyre Pharmaceuticals
Modality: Small Molecules
Administration: Oral

Overview

F230 is a selective endothelin receptor antagonist being developed as an oral small molecule therapy for the treatment of pulmonary arterial hypertension (PAH). By selectively blocking endothelin receptors, F230 aims to reduce vasoconstriction and vascular remodeling associated with PAH, potentially improving hemodynamics and patient outcomes. The drug is currently in early clinical development, with Phase 1 trials initiated in China[1][2].

Targets

EDNRA (Endothelin receptor type A)

Beyond the preview

Go deeper on F230.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on F230.

Explore the full profile